Shubham Pharmaceutical

Mumbai, India Founded: 2006 • Age: 20 yrs Listed
Serves as a distributor of a wide range of pharmaceutical drugs.

About Shubham Pharmaceutical

Shubham Pharmaceutical is a publicly listed company based in Mumbai (India) founded in 2006. It serves as a distributor of a wide range of pharmaceutical drugs. It operates on a B2B model. Its Indian entity Sun Pharmaceutical Industries Limited reported revenue of ₹61,674 Cr. Its focus areas include Pharmaceuticals, Distribution and Drug Supply. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.

Company details

Shubham Pharmaceutical, founded in 2006 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, distribution, and drug supply. Serves as a distributor of a wide range of pharmaceutical drugs. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.

Key Metrics
  • Market Cap
    ₹4,48,076 Cr

    SUNPHARMA · NSE

  • Share Price
    ₹1,870.00

    +0.13% today

  • Revenue
    ₹58,462 Cr

    FY 2025-26 · +11.2% YoY

  • EBITDA
    ₹15,184 Cr

    Margin 26.0%

  • Net Profit
    ₹12,429 Cr

    FY 2025-26 · +8.5% YoY

  • P/E (TTM)
    36.7x

    P/B 5.1x

  • ROE
    14.8%

    ROCE 18.7%

  • Debt / Equity
    0.04

    Interest cover 2.8x

Board of directors of Sun Pharmaceutical Industries Limited (Shubham Pharmaceutical)

Sun Pharmaceutical Industries Limited is the primary company behind Shubham Pharmaceutical. The board of Sun Pharmaceutical Industries Limited currently have 8 directors; the longest-serving is Dilip Shantilal Shanghvi, appointed in 2008. 20 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dilip Shantilal Shanghvi
DIN 00005588
Whole-time director01 Apr 200818 yrs 7 moSun Pharmaceutical Industries Limited
Pawan Kumar Goenka
DIN 00254502
Director21 May 20215 yrs 5 moSun Pharmaceutical Industries Limited
Aalok Dilip Shanghvi
DIN 01951829
Whole-time director01 Jun 20233 yrs 5 moSun Pharmaceutical Industries Limited
Rolf Karl Heinz Hoffmann
DIN 10200311
Director15 Jun 20233 yrs 5 moSun Pharmaceutical Industries Limited
Vidhi Dilip Shanghvi
DIN 06497350
Whole-time director22 May 20251 yr 5 moSun Pharmaceutical Industries Limited
Kirti Wardhaman Ganorkar
DIN 10620142
Managing Director01 Sep 20251 yr 2 moSun Pharmaceutical Industries Limited
Satyavati Berera
DIN 05002709
Director08 May 20266 moSun Pharmaceutical Industries Limited
Andreas Eugen Busch
DIN 11699735
Director12 May 20266 moSun Pharmaceutical Industries Limited

IPO & Listings of Shubham Pharmaceutical

Shubham Pharmaceutical is a publicly listed company on the NSE with ticker symbol SUNPHARMA in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: SUNPHARMA
  • Listed entitySun Pharmaceutical Industries Limited
  • Exchange sectorPharmaceuticals

Financials of Shubham Pharmaceutical

Exchange-reported figures of Sun Pharmaceutical Industries Limited, the listed company behind Shubham Pharmaceutical (NSE: SUNPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹58,462 Cr
+11.2% YoY
EBITDA
₹15,184 Cr
+5.4% YoY
Profit After Tax
₹12,429 Cr
+8.5% YoY
Net Worth
₹83,570 Cr
+15.7% YoY
Total Assets
₹90,020 Cr
+18.9% YoY
Total Debt
₹4,627 Cr
+95.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Balance sheet
Total assets90,02075,71871,31467,13153,37654,44758,774
Net worth83,57072,21863,66755,99548,01146,46345,264
Total debt4,6272,3623,2746,8861,2903,8698,315
Cash & bank11,60311,33210,5215,7705,0336,4466,488
Net working capital24,53922,74820,83516,90910,83114,13717,336
Cash flow
Cash from operations12,41914,07212,1354,9598,9856,1706,555
Cash from investing(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Cash from financing(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue16,19915,30014,61215,52114,47813,85112,95913,675
Revenue growth (YoY)+11.9%+10.5%+12.8%+13.5%+8.9%+9.5%--
Other income517724458579470464613466
EBITDA3,4754,2143,9544,4594,5273,4843,3543,693
EBITDA margin+21.6%+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%
Depreciation758739775732730701664631
Interest74.6799.6785.8978.3699.8674.8049.1451.51
Profit before tax3,1594,0993,5514,2274,1683,1733,2543,476
Tax1,1581,1888288261,0318701,094559
Net profit2,0022,9112,7243,4013,1372,3032,1612,918
EPS (₹)8.3012.1011.3014.0013.009.509.0012.10
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Profit before tax3,7944,9763,4501,7413078563,253
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Balance sheet
Total assets36,57636,64736,64432,64530,67835,63932,356
Net worth22,37123,90023,69423,74824,58826,93824,396
Total debt13,60511,94711,2277,7915,0747,3586,406
Cash & bank437911338421535361655
Net working capital10,19511,54910,4927,901(576)4,6035,492
Cash flow
Cash from operations6,5014,252(292)5077,636(417)1,306
Cash from investing(1,345)(251)(265)(686)(2,697)1,4521,483
Cash from financing(5,230)(3,836)474169(4,871)(1,000)(2,871)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,1425,7414,9245,6884,5485,5957,1796,181
Revenue growth (YoY)+35.0%+2.6%-31.4%-8.0%-11.2%+24.4%--
Other income81.0114062.9318072.7910413269.05
Total expenses4,4273,8083,5954,1883,3653,9734,1204,476
EBITDA1,7151,9331,3291,5001,1841,6223,0591,705
EBITDA margin+28.3%+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%
Depreciation316308326339336311305303
Interest277278217244248238232231
Profit before tax1,2031,4868491,0976721,1762,6541,240
Tax33237124039210843161283.81

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue16,19915,30014,61215,52114,47813,85112,95913,675
Revenue growth (YoY)+11.9%+10.5%+12.8%+13.5%+8.9%+9.5%--
Other income517724458579470464613466
EBITDA3,4754,2143,9544,4594,5273,4843,3543,693
EBITDA margin+21.6%+27.8%+27.2%+28.8%+31.4%+25.3%+26.2%+27.5%
Depreciation758739775732730701664631
Interest74.6799.6785.8978.3699.8674.8049.1451.51
Profit before tax3,1594,0993,5514,2274,1683,1733,2543,476
Tax1,1581,1888288261,0318701,094559
Net profit2,0022,9112,7243,4013,1372,3032,1612,918
EPS (₹)8.3012.1011.3014.0013.009.509.0012.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue58,46252,57848,49743,88638,65433,49832,838
Revenue growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
Other income3,2122,1511,3906351,075859652
Total expenses43,27838,17036,00432,41032,97829,33726,124
Employee cost11,4199,9739,4298,2967,3016,8626,362
EBITDA15,18414,40812,49311,4755,6774,1626,714
EBITDA margin+26.0%+27.4%+25.8%+26.2%+14.7%+12.4%+20.4%
Depreciation2,9382,5752,5572,5292,1442,0802,053
Interest339231238172127141303
Profit before tax15,11913,75211,0889,4084,4812,7995,010
Tax3,5542,7721,4398481,076515823
Net profit12,42911,4569,9908,6056,7175,7283,961
Net profit margin+21.3%+21.8%+20.6%+19.6%+17.4%+17.1%+12.1%
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus83,33071,97863,42755,75547,77146,22345,025
Shareholders' funds (net worth)83,57072,21863,66755,99548,01146,46345,264
Minority interest3102683,4593,3203,0553,0173,860
Secured loans0.000.000.000.000.007.83257
Unsecured loans4,6272,3623,2746,8861,2903,8618,057
Total debt4,6272,3623,2746,8861,2903,8698,315
Total liabilities90,02075,71871,31467,13153,37654,44758,774
Assets
Gross block60,32145,95044,32043,10038,70735,57935,116
Net block32,82222,58623,24824,06522,66521,55322,847
Capital work in progress3,0526,6445,3544,9731,2871,5671,220
Investments24,72318,35415,02614,82412,8499,61210,143
Inventories11,49310,2439,86810,5138,9258,9977,875
Sundry debtors15,51013,04611,24911,43910,4859,0619,421
Cash & bank balances11,60311,33210,5215,7705,0336,4466,488
Loans & advances4,3214,3173,2102,7672,7882,8082,973
Total current assets42,92738,93834,84930,48927,23127,31226,757
Total current liabilities18,38816,19014,01413,58016,40013,1759,420
Net working capital24,53922,74820,83516,90910,83114,13717,336
Total assets90,02075,71871,31467,13153,37654,44758,774
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10,2699,2864,6244,5086,2735,6777,062
Net cash from operating activities12,41914,07212,1354,9598,9856,1706,555
Net cash from investing activities(10,405)(5,183)(763)(7,220)(5,556)407(2,225)
Net cash from financing activities(2,513)(7,906)(6,710)2,376(5,193)(5,980)(5,715)
Net change in cash(498)9834,662115(1,765)596(1,386)
Closing cash11,60311,33210,5215,7705,0336,4466,488
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.2%+8.4%+10.5%+13.5%+15.4%+2.0%-
EBITDA growth+5.4%+15.3%+8.9%+102.1%+36.4%-38.0%-
PBT growth+9.9%+24.0%+17.9%+110.0%+60.1%-44.1%+31.5%
Net income growth+8.5%+14.7%+16.1%+28.1%+17.3%+44.6%-
Revenue CAGR (3Y)+10.0%+10.8%+13.1%+10.2%+10.0%+8.1%+1.3%
EBITDA CAGR (3Y)+9.8%+36.4%+44.3%+19.6%+3.7%-3.7%-12.7%
Profitability & leverage
Net income margin+19.8%+20.9%+19.9%+19.5%+8.8%+6.8%+12.8%
Return on capital employed+18.7%+19.5%+17.2%+16.8%+18.0%+13.6%+9.9%
Return on net worth+14.9%+16.2%+16.1%+16.5%+14.5%+11.1%+9.7%
Debt / equity0.040.040.080.080.050.130.22
Long-term debt / equity0.000.000.010.010.010.030.04
Interest cover2.771.962.401.923.606.796.50
Efficiency & per share
Fixed asset turnover1.101.161.111.071.040.950.98
Inventory turnover5.385.234.764.524.313.974.17
Debtors turnover4.094.334.284.003.963.623.59
EPS (₹)47.8445.5539.9135.3213.6412.1015.69
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)348.31301.00265.36233.38200.11193.65188.66
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue6,1425,7414,9245,6884,5485,5957,1796,181
Revenue growth (YoY)+35.0%+2.6%-31.4%-8.0%-11.2%+24.4%--
Other income81.0114062.9318072.7910413269.05
Total expenses4,4273,8083,5954,1883,3653,9734,1204,476
EBITDA1,7151,9331,3291,5001,1841,6223,0591,705
EBITDA margin+28.3%+34.3%+27.2%+26.5%+26.2%+29.2%+43.1%+28.5%
Depreciation316308326339336311305303
Interest277278217244248238232231
Profit before tax1,2031,4868491,0976721,1762,6541,240
Tax33237124039210843161283.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,75522,97720,27520,81215,58614,11612,532
Revenue growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
Other income1,7766345533291,1971921,511
Total expenses16,47716,39514,99417,32714,73811,9499,820
Employee cost2,9112,6912,3742,1572,0011,8061,703
EBITDA4,2776,5835,2813,4858482,1672,712
EBITDA margin+20.6%+28.7%+26.1%+16.7%+5.4%+15.4%+21.6%
Depreciation1,3121,2871,6011,6011,3501,236562
Interest948954784472388268408
Profit before tax3,7944,9763,4501,7413078563,253
Tax1,17174859150.3340713.1741.86
Net profit2,9454,2183,0523,356(1,338)9063,018
Net profit margin+14.2%+18.4%+15.1%+16.1%-8.6%+6.4%+24.1%
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital240240240240240240240
Reserves & surplus22,13123,66023,45423,50824,34826,69924,156
Shareholders' funds (net worth)22,37123,90023,69423,74824,58826,93824,396
Secured loans0.000.000.000.000.005.416.18
Unsecured loans13,60511,94711,2277,7915,0747,3536,400
Total debt13,60511,94711,2277,7915,0747,3586,406
Total liabilities36,57636,64736,64432,64530,67835,63932,356
Assets
Gross block20,68119,20018,25217,74517,19515,8128,245
Net block7,6137,3727,7378,7129,7139,6695,229
Capital work in progress8991,0847668538291,090597
Investments12,95212,41012,43012,61315,54915,53717,362
Inventories4,3023,9343,4243,9893,4043,4232,634
Sundry debtors10,16611,7028,8347,1254,2456,5856,168
Cash & bank balances437911338421535361655
Loans & advances1,7732,2342,3164,7081,3272,3292,089
Total current assets16,67918,78114,91316,2439,51112,69911,546
Total current liabilities6,4847,2314,4218,34310,0878,0966,055
Net working capital10,19511,54910,4927,901(576)4,6035,492
Total assets36,57636,64736,64432,64530,67835,63932,356
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash493327410420351315303
Net cash from operating activities6,5014,252(292)5077,636(417)1,306
Net cash from investing activities(1,345)(251)(265)(686)(2,697)1,4521,483
Net cash from financing activities(5,230)(3,836)474169(4,871)(1,000)(2,871)
Net change in cash(74.73)165(83.82)(9.25)68.4736.23(82.26)
Closing cash437911338421535361655
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-9.7%+13.3%-2.6%+33.5%+10.4%+12.6%-
EBITDA growth-35.0%+24.7%+51.5%+310.9%-60.9%-20.1%-
PBT growth-23.8%+44.3%+98.1%+467.4%-64.1%-73.7%+352.2%
Net income growth-30.2%+38.2%-9.1%+351.0%-247.6%-70.0%-
Revenue CAGR (3Y)-0.1%+13.8%+12.8%+18.4%+14.8%+16.3%+17.7%
EBITDA CAGR (3Y)+7.1%+98.0%+34.6%+8.7%+16.1%+327.4%+187.6%
Profitability & leverage
Net income margin+12.6%+18.4%+14.1%+8.1%-0.6%+6.0%+25.6%
Return on capital employed+14.5%+16.2%+12.2%+16.3%+7.5%+3.6%+11.9%
Return on net worth+12.7%+17.8%+12.1%+13.9%-5.2%+3.5%+13.6%
Debt / equity0.550.490.400.270.240.270.27
Long-term debt / equity0.310.260.400.270.200.130.06
Interest cover31.9618.0121.3125.06-77.3228.7318.98
Efficiency & per share
Fixed asset turnover1.041.231.131.190.941.171.60
Inventory turnover5.046.255.475.634.574.664.62
Debtors turnover1.902.242.543.662.882.212.24
EPS (₹)10.9317.6211.917.05(0.42)3.5113.38
Dividend per share (₹)16.0016.0013.5011.5010.007.504.00
Book value per share (₹)93.2499.6198.7698.98102.48112.28101.68

Similar companies to Shubham Pharmaceutical

Shubham Pharmaceutical has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
enterohealthcare.com2018Mumbai, India$59.67M817
India's leading healthcare products distribution platform
keimed.com2000Hyderabad, India$16.62M588
Temperature-sensitive medicines are distributed via cold chain logistics by Keimed.
sandor.co.in1995Hyderabad, India$8.98M161
Provider of medical equipment, devices, and drugs distribution services
Premium access

Detailed similar companies of Shubham Pharmaceutical

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Shubham Pharmaceutical

Shubham Pharmaceutical was founded in 2006.

Shubham Pharmaceutical is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

The primary company behind Shubham Pharmaceutical, Sun Pharmaceutical Industries Limited, reported revenue of ₹61,674 Cr for FY 2026, up 11% year on year.

Shubham Pharmaceutical, founded in 2006 in Mumbai, India, focuses on providing healthcare solutions, producing pharmaceutical products, distribution, and drug supply. Serves as a distributor of a wide range of pharmaceutical drugs. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.

Shubham Pharmaceutical's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.

Yes, Shubham Pharmaceutical is publicly traded on NSE under the ticker symbol SUNPHARMA.

Shubham Pharmaceutical operates through Sun Pharmaceutical Industries Limited.

The legal entities of Shubham Pharmaceutical currently have 10 directors, including Pawan Kumar Goenka, Anoop Anjanikumar Deshpande, Dilip Shantilal Shanghvi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available